Update on depression and age-related macular degeneration
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
PURPOSE OF REVIEW: This review updates the literature on depression in age-related macular degeneration (AMD). Treatment for AMD has been revolutionized since the 2004 review of depression and AMD. New data describing the prevalence of depression in AMD, as well as novel interventions for managing depression in AMD, are discussed. RECENT FINDINGS: Depression continues to be prevalent in AMD and new information is available on the pathways by which impaired vision leads to depression. Strategies for the treatment of depression in patients with impaired vision have evolved. SUMMARY: AMD is still a major risk factor for depression and people with activity restriction due to vision loss are at greatest risk. An integrated approach to depression management in older adults with impaired vision may be the best course of action.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522 · cited 1×
“Patients also improve in vision function and quality of life [13,14].”
BackgroundRanibizumab and bevacizumab for neovascular age-related macular degeneration
(2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102673 · Cited by 2,669
Causes and Prevalence of Visual Impairment Among Adults in the UnitedStates
(2004) · Archives of Ophthalmology · doi:10.1001/archopht.122.4.477 · Cited by 2,616
Cited by
Age-related macular degeneration
Mitchell, P., Liew, G., Gopinath, B., & Wong, T. Y. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31550-2 · Cited by 1,511
Age-Related Macular Degeneration
Thomas, C. J., Mirza, R. G., & Gill, M. K. (2021) · Medical Clinics of North America · doi:10.1016/j.mcna.2021.01.003 · Cited by 399
Major Depressive and Anxiety Disorders in Visually Impaired Older Adults
van der Aa, H. P. A., Comijs, H. C., Penninx, B. W. J. H., van Rens, G. H. M. B., & van Nispen, R. M. A. (2015) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.14-15848 · Cited by 280
Parravano, M., Petri, D., Maurutto, E., Lucenteforte, E., Menchini, F., Lanzetta, P., Varano, M., van Nispen, R. M. A., & Virgili, G. (2021) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2021.1557 · Cited by 126
Fernández-Vigo, J. I., Burgos-Blasco, B., Calvo-González, C., Escobar-Moreno, M. J., Shi, H., Jiménez-Santos, M., Valverde-Megías, A., Reche-Frutos, J., López-Guajardo, L., & Donate-López, J. (2021) · Archivos de la Sociedad Española de Oftalmología · doi:10.1016/j.oftal.2020.11.010 · Cited by 8
Metadata
- Authors
- Casten, R. J., & Rovner, B. W.
- Venue
- Current Opinion in Ophthalmology
- Published
- 2013-05
- Volume
- 24
- Issue
- 3
- Pages
- 239-243
- ISSN
- 1040-8738 (ISSN-L)
- OpenAlex
- W2092501667
- Cited by
- 110
- References
- 4
- FWCI
- 8.13
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Update on depression and age-related macular degeneration. https://app.cochat.ai/papers/10.1097/icu.0b013e32835f8e55
- The paper
- Casten, R. J., & Rovner, B. W. (2013). Update on depression and age-related macular degeneration. Current Opinion in Ophthalmology. https://doi.org/10.1097/icu.0b013e32835f8e55
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.